SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has promoted the company’s long time Vice President of Finance, Scott Boller, to Chief Financial Officer. SOFIE anticipates entering a revenue growth phase based on the recent news surrounding Lantheus Medical Imaging’s PSMA PET diagnostic PYLARIFY® and Life Molecular Imaging’s Amyloid probe, Neuraceq®.  PET Radiopharmacies have traditionally relied primarily on FDG PET dose sales, and this business has suffered from commoditization and price erosion – however these recent developments will contribute significant top line revenue as well as EBITDA starting in 2022.

Prior to joining SOFIE Scott spent most of his career on financial planning & analysis teams for both private and public corporations.  During those years he developed a focus on creating strong relationships between Finance and the business units it supports, creating cost-benefit analyses to objectively assess and rank business opportunities, leading budgeting and forecasting efforts, and identifying and implementing cost savings and process improvements. Scott is a U.S. Army veteran, holds a B.A. degree in East Asian Studies from the State University of New York at Albany, and an MBA degree from George Mason University.

SOFIE’s Chief Executive Officer, Patrick Phelps, states, “2020 was a real test and our company faced massive headwinds associated with the impact of the COVID pandemic. Scott was already well regarded by our board and management team going into last year but truly solidified himself as a battle tested force and leader in our company. He has my full trust and confidence, and we expect that he will continue to do great things in our organization as we prepare for a massive dose uptick fueled by the FDA’s recent approvals in prostate cancer and neurodegenerative disease.”

Philipp Czernin, SOFIE’s Chief Revenue Officer added, “There is a growing interest in nuclear medicine and while most of this interest is obviously focused on Theranostics IP, there is also significant interest in supply chain and subsequently in radiopharmacy infrastructure. I am confident that Scott is exactly who we need to guide us through this next phase, and I have seen the level of respect he commands at the board level and in his interactions with our current as well as prospective partners and investors. We are lucky to have had an opportunity to retain him and to make him our Chief Financial Officer.”